Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. - Test2 - elhamkhani - TriplyDB

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

http://www.wikidata.org/entity/Q34316288

about

Drugging topoisomerases: lessons and challenges Immunodetection of human topoisomerase I-DNA covalent complexes Saturation diving alters folate status and biomarkers of DNA damage and repair Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues Ionizing radiation-induced γ-H2AX activity in whole blood culture and the risk of lung cancer ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Creating and virtually screening databases of fluorescently-labelled compounds for the discovery of target-specific molecular probes.Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.γ-H2AX and other histone post-translational modifications in the clinic.Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay NANOG modulates stemness in human colorectal cancer.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Lessons learned from radiation oncology clinical trials.Translational research in oncology--10 years of progress and future prospects.Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant gene associated with Angelman syndrome

P2860

Q27000099-A7509747-318D-469D-A66D-3CA1A1CA3221 Q27324108-358976B9-7EB7-45BD-A591-7D72CDCAEA4A Q28480543-A6990C8D-868C-484A-B6E8-47A8D4B771FA Q33897223-178FFBEA-FD72-42CA-8703-1B8FEDF5515C Q34531543-3A2FCA1F-F55F-43B3-BF4C-32048C58A084 Q34539540-DEF38017-97B3-447F-AF7B-DA04D219E23E Q34614944-1B1DF2FF-93F1-45F0-B8AD-A8B0D7A58CE2 Q34852332-44B11426-8C4B-4705-B7A0-CA1AFC7E1A97 Q35195304-4EE6AD28-C95A-4273-B5BD-973AA7B283F9 Q35201518-843A2D36-7729-462C-A8F5-35305D20CDB3 Q35230342-1DAE1DF7-A0A2-4547-932B-B306DC37C15D Q35782905-1DAF67C7-893D-4DDD-A31D-672A90306AD1 Q35836463-8F47E128-6449-4F00-99BF-A1F8474E44D3 Q36019818-7D759231-080E-45FD-B570-6DF8E0BED38D Q36162494-70C5BAF7-0E17-406F-BC72-8CA84305DD07 Q36164329-EAC80A89-DE86-4680-93AF-EAC80A1E5AA0 Q36270038-78135F0A-DEF5-4641-8F9B-E8CCBE1CCEAE Q36565835-915059B8-8EE3-40BA-9AD2-D3FEE820368B Q36568915-517D2F2E-EB51-4DAC-B1D6-0632EA248941 Q37059846-0B6DD1A2-9CA9-48DE-8C74-7AC54C942F77 Q37544686-A4EDD890-2CB9-4220-863A-17004DCE8FE2 Q37662264-D1716457-F3FA-4F36-889F-83005A5C3FCE Q37662359-FD257B94-9E57-4880-9051-CF0478C8715E Q38257126-97CF69D5-86E0-445C-B45E-FF6B79660DB6 Q38963126-B4E83947-5C1B-4728-90E9-B1641BF3FA52 Q38963129-4D2D7B82-95CC-4C97-A5A6-D0688E59E899 Q39255471-454AA7B8-C371-4F5F-AD31-4D7FE3C9BD15 Q47730914-598CEE7B-4499-4B68-8351-07DE4E5BCA90 Q52571240-F456CF12-4D52-46EF-8BEF-B4BE3FF60477 Q57168803-3F4D7CDC-A6B6-4BAE-82C8-9AE52586475B

P2860

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

http://www.wikidata.org/entity/Q34316288

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Development of a validated imm ...... somerase I inhibitor activity.

@ast

Development of a validated imm ...... somerase I inhibitor activity.

@en

Development of a validated imm ...... somerase I inhibitor activity.

@nl

type

label

Development of a validated imm ...... somerase I inhibitor activity.

@ast

Development of a validated imm ...... somerase I inhibitor activity.

@en

Development of a validated imm ...... somerase I inhibitor activity.

@nl

prefLabel

Development of a validated imm ...... somerase I inhibitor activity.

@ast

Development of a validated imm ...... somerase I inhibitor activity.

@en

Development of a validated imm ...... somerase I inhibitor activity.

@nl

P1433

Q34316288-C97E9BB4-7818-43D2-B4EB-73DC2850331E

P1476

Q34316288-89F74DE0-9D2F-44A9-854C-D00E1A031683

P2093

Q34316288-1F678EF9-4AC0-41A5-AD5C-7A84EC9681AB

Q34316288-26AA05A7-5E04-431C-9342-F93531201F4A

Q34316288-2790671D-A666-4B56-9576-DA6A4C5A4755

Q34316288-37E23A03-AEC9-4658-AFBD-48E9A78A2195

Q34316288-419038C1-FBF1-4B7D-BAD9-29D1C91615BD

Q34316288-63CC01F6-9EFE-4C24-8D46-0FCE3B266915

Q34316288-A1128D1E-2D88-4BE9-9606-1F05CE20964B

Q34316288-B40FF0CD-065B-44E9-8B84-5BAC530F97A9

Q34316288-BCDBEA27-49A0-4137-8B98-5BC53A050CD0

Q34316288-C3962124-2B60-40C0-874C-036E54ABEB37

P2860

Q34316288-0509A1C1-EACB-424A-A484-CA66AE6237FC

Q34316288-0CB6042B-66AD-4041-873E-E3A4C3855E0E

Q34316288-114F3D60-5641-43D6-BA90-70CC970D2E79

Q34316288-11D904AB-8D68-46F1-9B19-EAF7955F2BDE

Q34316288-12FC48F0-2C00-41D8-8723-B11F4ECA0475

Q34316288-137BD53E-3F3D-4E0B-B5F8-0591F387A1CC

Q34316288-1BD58F22-B05F-4EE6-84B5-2FA1E2E6E7DB

Q34316288-24705071-9762-49D8-8758-235B9DA3A9BA

Q34316288-28447C8F-0075-4419-875C-C6C721A88857

Q34316288-3611974A-ECD5-4BBE-AE1E-40B20C708F79

P304

Q34316288-D2BC8013-B9F3-4DDB-8082-EBB084184935

P31

Q34316288-D2767356-2740-4E11-895A-59E48DB9A041

P356

Q34316288-C9CD75F3-5D89-4AD5-8BD4-BE35DD6737AD

P407

Q34316288-34176C3B-D211-4B07-85AD-7A5943A87D9B

P433

Q34316288-C8EB4EF3-3BBC-4A2F-A20E-874D1894794F

P478

Q34316288-993B06BC-78FC-4601-A06A-50F0929F33FA

P50

Q34316288-E68FC73B-548E-45A1-AC94-5381166C488F

P577

Q34316288-CB9209D0-4719-44A6-991F-7CACC17A8B00

P698

Q34316288-2612F5AB-18A0-441A-BF0D-646AD4A7EB31

P921

Q34316288-DA87BB4C-FFCC-4FB9-A4AF-CD361B1857F2

P932

Q34316288-CA198B0B-9655-4830-A3CF-E0EF9E0B7759

P356

1078-0432.CCR-09-3076

P1433

Clinical Cancer Research

P1476

Development of a validated imm ...... somerase I inhibitor activity.

@en

P2093

Brian Tabb

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Joseph Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Melinda Hollingshead

http://www.w3.org/2001/XMLSchema#string

National Cancer Institute Phase 0 Clinical Trials Team

http://www.w3.org/2001/XMLSchema#string

Ralph E Parchment

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

Scott Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Megabase chromatin domains involved in DNA double-strand breaks in vivo

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139

A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage

H2AX: the histone guardian of the genome

Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison

GammaH2AX and cancer

Topoisomerase I inhibitors: camptothecins and beyond

Recombinational DNA double-strand breaks in mice precede synapsis

Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.

P304

5447-5457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-3076

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20924131

http://www.w3.org/2001/XMLSchema#string

P921

immunofluorescence microscopy

P932

2982895

http://www.w3.org/2001/XMLSchema#string